Search

Your search keyword '"Garufi S"' showing total 101 results

Search Constraints

Start Over You searched for: Author "Garufi S" Remove constraint Author: "Garufi S"
101 results on '"Garufi S"'

Search Results

1. OC.10.3 THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN’S DISEASE

3. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

4. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

5. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

6. P439 Effectiveness of Ustekinumab on Crohn’s disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

7. P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

8. P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

9. P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease

10. T05.01.5 FACTORS AFFECTING THE QUALITY OF BOWEL PREPARATION FOR COLONOSCOPY IN THE ELDERLY: A RETROSPECTIVE ANALYSIS OF A PROSPECTIVE COHORT

11. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2

12. T05.01.3 SAFETY OF NER1006 IN ELDERLY: A POST-HOC ANALYSIS OF A PROSPECTIVE, MULTICENTER COHORT

13. T04.01.19 USTEKINUMAB IN CROHN'S DISEASE: REAL-WORLD OUTCOMES FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD) – PRELIMINARY RESULTS

14. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

15. PC.01.2 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB AND ADALIMUMAB IN CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

16. FACTORS AFFECTING THE QUALITY OF BOWEL PREPARATION FOR COLONOSCOPY IN THE ELDERLY: A RETROSPECTIVE ANALYSIS OF A PROSPECTIVE COHORT

18. EFFECTIVENESS AND TOLERABILITY OF NER1006 COMPARED TO HIGHER-VOLUME PEG PREPARATIONS FOR COLONOSCOPY: A PROSPECTIVE, MULTICENTER OBSERVATIONAL STUDY

19. P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results

20. P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

21. P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2

22. P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn’s disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)

25. P.07.1 ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) ARE LESS LIKELY TO PERSIST ON ANTI-TNF THERAPY COMPARED WITH YOUNGER PATIENTS. DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

26. OC.12.3 SPOSIB SB2 – A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2 (FLIXABI®): INTERIM ANALYSIS

29. A real life comparison of the efficacy of adalimumab versus golimumab in moderate-to-severe ulcerative colitis. A multicenter experience from the sicilian network for inflammatory bowel disease (SN-IBD)

30. Search for gravitational waves from Scorpius X-1 in the first Advanced LIGO observing run with a hidden Markov model

31. Search for continuous gravitational waves from neutron stars in globular cluster NGC 6544

32. P737 SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis

33. P545 Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

34. OC.02.3 A REAL LIFE COMPARISON OF THE EFFECTIVENESS OF ADALIMUMAB VERSUS GOLIMUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS. A MULTICENTRE EXPERIENCE FROM A REGIONAL NETWORK FOR INFLAMMATORY BOWEL DISEASE

37. Intrinsic limits on resolutions in muon and electron-neutrino charged-current events in the KM3NeT/ORCA detector

38. First Search for Gravitational Waves from Known Pulsars with Advanced LIGO

39. Radiofrequency Ablation for Treatment of Refractory Gastric Antral Vascular Ectasia: A Systematic Review of the Literature

40. Search for intermediate mass black hole binaries in the first observing run of Advanced LIGO

41. Improved analysis of GW150914 using a fully spin-precessing waveform model

42. Observing gravitational-wave transient GW150914 with minimal assumptions

49. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

50. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis

Catalog

Books, media, physical & digital resources